[go: up one dir, main page]

WO2007012066A3 - TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF - Google Patents

TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF Download PDF

Info

Publication number
WO2007012066A3
WO2007012066A3 PCT/US2006/028323 US2006028323W WO2007012066A3 WO 2007012066 A3 WO2007012066 A3 WO 2007012066A3 US 2006028323 W US2006028323 W US 2006028323W WO 2007012066 A3 WO2007012066 A3 WO 2007012066A3
Authority
WO
WIPO (PCT)
Prior art keywords
truncated
derivatives
oxidized thymosin
thymosin
oxidized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/028323
Other languages
French (fr)
Other versions
WO2007012066A2 (en
Inventor
Elizabeth Taylor
Robert Goodenow
John Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRANNUS BIOSCIENCES
Original Assignee
GRANNUS BIOSCIENCES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GRANNUS BIOSCIENCES filed Critical GRANNUS BIOSCIENCES
Priority to EP06788075A priority Critical patent/EP1913013A2/en
Priority to AU2006269852A priority patent/AU2006269852A1/en
Priority to CA002616125A priority patent/CA2616125A1/en
Publication of WO2007012066A2 publication Critical patent/WO2007012066A2/en
Publication of WO2007012066A3 publication Critical patent/WO2007012066A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of truncated oxidized thymosin β4 in therapy, such as in the treatment of diseases or conditions associated with inflammation.
PCT/US2006/028323 2005-07-19 2006-07-19 TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF Ceased WO2007012066A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06788075A EP1913013A2 (en) 2005-07-19 2006-07-19 Truncated oxidized thymosin beta4 and derivatives thereof
AU2006269852A AU2006269852A1 (en) 2005-07-19 2006-07-19 Truncated oxidized thymosin beta4 and derivatives thereof
CA002616125A CA2616125A1 (en) 2005-07-19 2006-07-19 Truncated oxidized thymosin .beta.4 and derivatives thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70064105P 2005-07-19 2005-07-19
US60/700,641 2005-07-19

Publications (2)

Publication Number Publication Date
WO2007012066A2 WO2007012066A2 (en) 2007-01-25
WO2007012066A3 true WO2007012066A3 (en) 2007-06-07

Family

ID=37669572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028323 Ceased WO2007012066A2 (en) 2005-07-19 2006-07-19 TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF

Country Status (4)

Country Link
EP (1) EP1913013A2 (en)
AU (1) AU2006269852A1 (en)
CA (1) CA2616125A1 (en)
WO (1) WO2007012066A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514383A (en) * 2008-03-17 2011-05-06 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド Improved beta thymosin fragment
EP3744729B1 (en) * 2009-01-16 2023-03-01 Sederma Peptides, compositions comprising them and cosmetic and dermopharmaceutical uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602519B1 (en) * 1998-03-28 2003-08-05 The University Court Of The University Of Glasgow Oxidized thymosin β4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602519B1 (en) * 1998-03-28 2003-08-05 The University Court Of The University Of Glasgow Oxidized thymosin β4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GONDO H. ET AL.: "Differential expression of the human thymosin-beta 4 gene in lymphocytes, macrophages, and granulocytes", J. IMMUNOL., vol. 139, no. 11, 1 December 1987 (1987-12-01), pages 3840 - 3848, XP003013717 *

Also Published As

Publication number Publication date
EP1913013A2 (en) 2008-04-23
WO2007012066A2 (en) 2007-01-25
CA2616125A1 (en) 2007-01-25
AU2006269852A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
CL2007002261A1 (en) COMPOUNDS DERIVED FROM IMIDAZO [1,2-B] PIRIDAZINA, QUINASA INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF CANCER.
WO2004041269A3 (en) New use for pharmaceutical composition
MY147247A (en) Organic compounds and their uses
WO2004071382A3 (en) Substituted heterocycles
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
SI1909843T1 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation, and their use in the pharmaceutical field
EP1912650B8 (en) Use of flibanserin in the treatment of obesity
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
WO2009156182A3 (en) Uracil derivatives and use thereof
WO2007129114A3 (en) Aptamers directed to recombinant muc1
NO20070892L (en) Compositions of N-glycolylneuraminic acid and their use in the treatment of colds.
IL194880A (en) Aminothiazole derivatives, their use in the treatment of diseases and pharmaceutical compositions comprising them
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2007041614A3 (en) Long acting vegf inhibitors and methods of use
WO2007108004A3 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
BRPI0914462A2 (en) "topical composition, method of preventing or reducing the occurrence of acne treatment and use of a composition"
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
WO2007012066A3 (en) TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF
WO2005013946A3 (en) Methods of treatment inflammatory bowel with lxr agonists
WO2006124477A3 (en) Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2616125

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006269852

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006788075

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006269852

Country of ref document: AU

Date of ref document: 20060719

Kind code of ref document: A